| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:DDR-TRK-1
CAS:1934246-19-1
Purity:99.00% Package:1mg;2mg;5mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:DDR-TRK-1
CAS:1934246-19-1
Purity:99.86% Package:1mg/RMB 774;2mg/RMB 1150;5mg/RMB 1790
|
DDR-TRK-1
(DDR1 inhibitor 6j) manufacturers
- DDR-TRK-1
-
- $117.00 / 1mg
-
2025-04-28
- CAS:1934246-19-1
- Min. Order:
- Purity: 99.86%
- Supply Ability: 10g
- DDR-TRK-1
-
- $117.00 / 1mg
-
2025-04-27
- CAS:1934246-19-1
- Min. Order:
- Purity: 99.86%
- Supply Ability: 10g
|
| | DDR-TRK-1
(DDR1 inhibitor 6j) Basic information |
| Product Name: | DDR-TRK-1
(DDR1 inhibitor 6j) | | Synonyms: | DDR-TRK-1
(DDR1 inhibitor 6j);DDR-TRK-1;7-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-2-(5-pyrimidinyl)-, (4R)-;DDRTRK1,DDR TRK 1;DDR-TRK-1, 10 mM in DMSO | | CAS: | 1934246-19-1 | | MF: | C26H23F3N6O | | MW: | 492.5 | | EINECS: | | | Product Categories: | | | Mol File: | 1934246-19-1.mol |  |
| | DDR-TRK-1
(DDR1 inhibitor 6j) Chemical Properties |
| Boiling point | 609.3±55.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 12.84±0.70(Predicted) | | form | powder | | color | white to beige | | optical activity | [α]/D -25 to -20°, c =0.5 in methanol |
| | DDR-TRK-1
(DDR1 inhibitor 6j) Usage And Synthesis |
| Uses | DDR-TRK-1 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM. DDR-TRK-1 also inhibits TRK family. | | Biological Activity | DDR-TRK-1 was shown to inhibit the kinase activity of Discoidin Domain Receptor 1 (DDR1) with an IC50 value of 9.4 nM. DDR receptors are linked to the progression of various human diseases, including fibrotic disorders such as pulmonary fibrosis, as well as atherosclerosis and cancer. DDR-TRK-1 showed a therapeutic effect in a mouse model of pulmonary fibrosis and inhibited Panc-1 pancreatic cancer cell colony formation and migration. DDR-TRK-1 also inhibits the TRK family kinases TRKA, TRKB, and TRKC, which are selectively expressed in neuronal tissue. DDR-TRK-1N is the negative control compound. | | in vivo | DDR-TRK-1 prevents these BLM-induced pathological changes in a dose-dependent manner. These results agree with the expression levels of fibrotic markers in lung tissue lysates, including fibronectin and α-smooth muscle actin (SMA). Further analyses also reveal that the administration of DDR-TRK-1 cause a dose-dependent suppression in the content of hydroxyproline, a unique amino acid found in collagen. The above data collectively indicate the promising therapeutic potential of DDR-TRK-1 against the BLM-induced pulmonary fibrosis[1]. | | References | [1] Zhen Wang, et al. Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. J Med Chem. 2016 Jun 23; 59(12): 5911–5916. DOI:10.1021/acs.jmedchem.6b00140 |
| | DDR-TRK-1
(DDR1 inhibitor 6j) Preparation Products And Raw materials |
|